Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

Recent Developments & HighlightsTwo New England Journal of Medicine Publications
In June 2013, The New England Journal of Medicine (NEJM) published results from two Phase II studies of ibrutinib:  PCYC 1104-CA, a Phase II study evaluating  the safety and efficacy of ibrutinib monotherapy in patients with relapsed/refractory MCL; and PCYC 1102-CA, a Phase Ib/II study examining the safety and efficacy of ibrutinib monotherapy for the treatment of patients with relapsed/refractory CLL/ SLL, some of whom had deletion of part of chromosome 17 (del 17p). These data suggested ibrutinib may be effective and generally well-tolerated in patients with relapsed/refractory MCL and in patients with relapsed/refractory CLL/SLL. Both studies were originally presented at the annual meeting of the American Society of Hematology (ASH) in December 2012. Updated results from PCYC 1104-CA were presented at the European Hematology Association (EHA) Annual Meeting in June 2013.

Conferences and Presentations in June 2013
In June, Pharmacyclics and its collaborators presented 5 oral and 6 poster presentations on ibrutinib at three annual conferences: American Society of Clinical Oncology (ASCO), EHA, and the International Conference on Malignant Lymphoma (ICML).  These conferences showcased updated and expanded data in high risk CLL, relapsed or refractory MCL, and relapsed or refractory diffuse large B-cell lymphoma (DLBCL).  Also at these conferences ibrutinib data in two new areas were presented: Waldenstrom's Macroglobulinemia (WM) and frontline DLBCL in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). All oral presentations made at these conferences have been filed in Form 8-K's with the SEC.

Selected Clinical Trials Initiated with Ibrutinib Over the Last 18 MonthsCLL/SLL

  • RESONATE™ (PCYC-1112) Phase III study of ibrutinib versus ofatumumab in patients wi
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    2. Pharmacyclics Reports First Quarter 2013 Results
    3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... MILFORD, Pa. , Sept. 17, 2014  Fortune ... has officially changed its name to Manzo Pharmaceuticals, Inc. ... change to take effect today, September 17, 2014. Also ... split. The approval is a pivotal event ... Manzo . Mr. Manzo explained, "We could not proceed ...
    (Date:9/17/2014)... -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), a ... an unsolicited, non-binding proposal from Endo International plc (NASDAQ: ... outstanding shares of Auxilium common stock at a price ... subject to due diligence, financing and other conditions. A ... from Endo on Friday evening is reproduced below. ...
    (Date:9/17/2014)... -- Mindray (NYSE: MR)announced its new generation DC-70 ultrasound ... been showcased for the first time at ISUOG in ... is scheduled for availability in the U.S. market in ... efficient workhorse in the mid-range segment, the DC-70 combines ... user experience including a gesture-sensitive touch screen, delivering accurate ...
    Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Quality Exams at Your Fingertips 2
    ... July 29 Micromet, Inc.,(Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune,diseases, today announced ... audio,webcast on Thursday, August 7, 2008, at 9:00 ... discuss its second quarter 2008 financial,results. Micromet anticipates ...
    ... July 28 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ... study of intravenous (i.v.) peramivir administered via a ... treatment of seasonal,influenza. The trial, conducted by BioCryst,s ... primary endpoint of improvement in the median time ...
    Cached Medicine Technology:Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 2BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 4BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 5
    (Date:9/17/2014)... (PRWEB) September 17, 2014 With ... have special functions of adjusting human body physiology, ... won great popularity with a variety of specific ... food in China reached RMB187.4 billion, up 12.0% ... during 2006-2013. , China's health product industry is ...
    (Date:9/17/2014)... NetDimensions (AIM: NETD; OTCQX: NETDY), a global ... the opening of the 2014 Next Steps user conference ... very excited to meet up in Chicago again this ... Steps from our clients and partners, which shows how ... look forward to some very engaging and fun days ...
    (Date:9/17/2014)... 17, 2014 Researchers say patients with ... least likely to have good outcomes with chemotherapy treatment. ... findings. Click here to read it now. ... Levine Cancer Institute in North Carolina analyzed 30 published ... the 137 patients with sarcomatoid mesothelioma had ...
    (Date:9/17/2014)... 17, 2014 There’s something changing ... girls of all ages an all-natural option for ... by women, for women, announces the launch of ... to relieve the symptoms commonly associated with ... , As a lifelong health enthusiast and ...
    (Date:9/17/2014)... September 17, 2014 Request A Test ... testing, is offering 10% off drug testing through ... all drug tests, including those ordered by employers for workplace ... advantage of this discount by using promo code DRUG10 when ... in positives on workplace drug testing, especially for marijuana or ...
    Breaking Medicine News(10 mins):Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 2Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 3Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 4Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 3Health News:Doctors Find Lower Treatment Response in Those with Rare Type of Mesothelioma, According to Surviving Mesothelioma 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 3Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 4Health News:Request A Test Can Save You 10% on Drug Testing 2Health News:Request A Test Can Save You 10% on Drug Testing 3
    ... Jeff Klein Renowned for IVF Success, NEWBURGH, ... clinical affiliate of The Mount Sinai Hospital, is ... region with the addition of,Reproductive Endocrinologist Jeffrey Klein, ... medical director of the Westchester division of,Reproductive Medicine ...
    ... PITTSBURGH and PLYMOUTH MEETING, Pa., March 12 ... Maintenance,Management Systems (CMMS) for the healthcare industry and ... approaches to improving,patient care, announce the availability of ... and recall alert applications., This new ...
    ... air purifier,delivers cleaner and healthier air. It effectively ... pollutants that affect us every day at work ... value through the unbeatable,combination of consumer benefits., ... and Ozone Cause Severe Health Problems, Millions ...
    ... University of Warwick has uncovered exactly how the bacterium ... The same research could also open up MRSA to ... designer antibiotics to use against a range of other ... fatal pneumonia infections a year in children. In the ...
    ... . , Quebec City, March 12, 2008A research ... identified genetic markers that allow the selection of eggs ... after in vitro fertilization (IVF). This finding could both ... diminish the risk of multiple pregnancies. The details of ...
    ... 12, 2008 AstraZeneca (NYSE: AZN) announced today that ... III studies for vandetanib, the companys investigational, once-daily oral ... lung cancer (NSCLC). The two studies ZODIAC (ZACTIMA ... and ZEAL (ZACTIMA Efficacy with Alimta in Lung cancer) ...
    Cached Medicine News:Health News:SLCH Brings Infertility Specialist to Region 2Health News:Four Rivers Software Systems and ECRI Institute Announce New, Real-Time Interfaces to Improve Inventory Management and Patient Safety Alert and Recall Tracking 2Health News:Four Rivers Software Systems and ECRI Institute Announce New, Real-Time Interfaces to Improve Inventory Management and Patient Safety Alert and Recall Tracking 3Health News:LightAir Cleans the Air From the Smallest and Most Dangerous Particles Without Generating Ozone 2Health News:Research could put penicillin back in battle against antibiotic resistant bugs that kill millions 2Health News:Researchers develop a method to select eggs with the best chance of leading to successful pregnancy 2Health News:Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib 2
    ... Gemini is the newest addition to Laserscopes ... distinct wavelengths to choose from, 1064nm Nd:YAG ... in an exploding non-invasive aesthetic laser market ... and effectiveness while maintaining the safety and ...
    ... Surgical Laser System is designed for ... high-power, dual-wavelength system designed for urology, ... surgery, neurosurgery, pulmonary surgery and gastroenterology ... vaporizes and coagulates tissue with minimal ...
    ... biolitecs Ceralas D 980 nm diode laser ... bloodless field for most surgical procedures. ... cuts optically without collateral tissue damage ... coagulates blood instantly and seals small blood ...
    ... is a monoclonal antibody based ... confirmatory identification of Neisseria gonorrhoeae. ... isolated, viable or fresh cultures. ... two minute rotation, a positive ...
    Medicine Products: